Traws Pharma Inc Total Assets
Traws Pharma Inc total assets. Based on the latest financial reports, Traws Pharma Inc (TRAW) holds total assets worth $11.47 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see TRAW company net worth for the company's overall valuation and market capitalisation.
Total Assets of Traws Pharma Inc (2011–2025)
Total assets of Traws Pharma Inc from 2011 to 2025. This chart illustrates how Traws Pharma Inc's total assets have evolved over time, based on quarterly financial data. See TRAW stock price for real-time trading data and today's change.
Traws Pharma Inc - Asset Composition Analysis
Traws Pharma Inc Total Assets Breakdown (December 2025)
Traws Pharma Inc total assets breakdown as of December 2025. Traws Pharma Inc's total assets of $11.47 Million consist of 75.2% current assets and 24.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 36.0% |
| Accounts Receivable | $3.79 Million | 35.7% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $2.53 Million | 23.8% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2011–2025)
This chart illustrates how Traws Pharma Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Traws Pharma Inc short-term liquidity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Traws Pharma Inc's current assets represent 75.2% of total assets in 2025, a decrease from 85.6% in 2011.
- Cash Position: Cash and equivalents constituted 36.0% of total assets in 2025, down from 60.8% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 23.0% of total assets, an increase from 0.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 35.7% of total assets.
Traws Pharma Inc Competitors by Total Assets
Key competitors of Traws Pharma Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Traws Pharma Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.93 | 2.09 | 8.53 |
| Quick Ratio | 0.93 | 2.09 | 8.53 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-712.00K | $8.02 Million | $52.91 Million |
Traws Pharma Inc - Advanced Valuation Insights
This section examines the relationship between Traws Pharma Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.49 |
| Latest Market Cap to Assets Ratio | 0.44 |
| Asset Growth Rate (YoY) | -57.5% |
| Total Assets | $10.62 Million |
| Market Capitalization | $4.64 Million USD |
Valuation Analysis
Below Book Valuation: The market values Traws Pharma Inc's assets below their book value (0.44x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Traws Pharma Inc's assets decreased by 57.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Traws Pharma Inc (2011–2025)
The table below shows the annual total assets of Traws Pharma Inc from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $10.62 Million | -57.47% |
| 2024-12-31 | $24.96 Million | +10.05% |
| 2023-12-31 | $22.68 Million | -42.39% |
| 2022-12-31 | $39.37 Million | -29.03% |
| 2021-12-31 | $55.48 Million | +177.58% |
| 2020-12-31 | $19.99 Million | -15.58% |
| 2019-12-31 | $23.67 Million | +32.09% |
| 2018-12-31 | $17.92 Million | +259.97% |
| 2017-12-31 | $4.98 Million | -78.57% |
| 2016-12-31 | $23.23 Million | -0.90% |
| 2015-12-31 | $23.45 Million | -50.47% |
| 2014-12-31 | $47.34 Million | -54.98% |
| 2013-12-31 | $105.15 Million | +25.40% |
| 2012-12-31 | $83.85 Million | +1779.25% |
| 2011-12-31 | $4.46 Million | -- |
About Traws Pharma Inc
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonu… Read more